SI
SPPI

Sofinnova Investments’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Sofinnova Investments’s Portfolio SPPI Stock Details SPPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-15,000
Closed -$241K – 71
2018
Q1 		$241K Buy
+15,000
New +$297K 0.04% 44

Other funds holding SPPI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Sofinnova Investments's SPPI Position: Q3 2018 in Review

Sofinnova Investments sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q3 2018, closing a stake of 169,965 shares — an estimated $3.56M sold.

Sofinnova Investments first reported a position in SPPI in Q2 2018 and held it in 1 quarter. The position peaked at $3.56M in Q2 2018. 190 funds tracked by Wall St. Rank hold SPPI as of Q3 2018.

  • Sofinnova Investments reported no remaining Spectrum Pharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
  • Sofinnova Investments sold 169,965 Spectrum Pharmaceuticals Inc shares in Q3 2018, an estimated $3.56M.
  • Sofinnova Investments first reported a position in Spectrum Pharmaceuticals Inc in Q2 2018 and held it in 1 quarter.
  • Sofinnova Investments's Spectrum Pharmaceuticals Inc position peaked at $3.56M in Q2 2018.
  • 190 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q3 2018.

Based on Sofinnova Investments's 13F filing for Q3 2018, filed 15 Nov 2018.